- Home
- IMCR vs COMM Comparison
IMCR vs COMM Comparison
Compare IMCR & COMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- COMM
- Stock Information
- Founded
- IMCR 2008
- COMM 1976
- Country
- IMCR United Kingdom
- COMM United States
- Employees
- IMCR N/A
- COMM N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- COMM Radio And Television Broadcasting And Communications Equipment
- Sector
- IMCR Health Care
- COMM Technology
- Exchange
- IMCR Nasdaq
- COMM Nasdaq
- Market Cap
- IMCR 1.8B
- COMM 1.8B
- IPO Year
- IMCR 2021
- COMM 2013
- Fundamental
- Price
- IMCR $33.38
- COMM $14.89
- Analyst Decision
- IMCR Buy
- COMM Hold
- Analyst Count
- IMCR 10
- COMM 6
- Target Price
- IMCR $58.13
- COMM $10.30
- AVG Volume (30 Days)
- IMCR 315.0K
- COMM 10.2M
- Earning Date
- IMCR 08-07-2025
- COMM 08-04-2025
- Dividend Yield
- IMCR N/A
- COMM N/A
- EPS Growth
- IMCR N/A
- COMM N/A
- EPS
- IMCR N/A
- COMM 3.34
- Revenue
- IMCR $356,145,000.00
- COMM $4,751,500,000.00
- Revenue This Year
- IMCR $27.43
- COMM $21.14
- Revenue Next Year
- IMCR $8.64
- COMM $8.73
- P/E Ratio
- IMCR N/A
- COMM $4.52
- Revenue Growth
- IMCR 26.78
- COMM 20.87
- 52 Week Low
- IMCR $23.15
- COMM $2.94
- 52 Week High
- IMCR $39.33
- COMM $15.85
- Technical
- Relative Strength Index (RSI)
- IMCR 49.64
- COMM 78.12
- Support Level
- IMCR $31.02
- COMM $14.65
- Resistance Level
- IMCR $33.73
- COMM $15.85
- Average True Range (ATR)
- IMCR 1.49
- COMM 0.78
- MACD
- IMCR -0.03
- COMM 0.31
- Stochastic Oscillator
- IMCR 44.61
- COMM 89.84
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).